Associated Papers
Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G et al.
Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 2019
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Select a paper to view details